The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial1
Open accessAbstract
OBJECTIVES: The non-small cell lung cancer (NSCLC) meta-analysis suggested a survival benefit for cisplatin-based chemotherapy when given in addition to surgery, radical radiotherapy or 'best supportive care'. However, it included many small trials and trials with differing eligibility criteria and chemotherapy regimens. The aim of the Big Lung Trial was therefore to run a large pragmatic trial to confirm the survival benefits seen in the meta-analysis. METHODS: In the surgery setting, a total of 381 patients were randomised to chemotherapy (C, 192 patients) or no chemotherapy (NoC, 189 patients). C was three 3-weekly cycles of cisplatin/vindesine, mitomycin/ifosfamide/cisplatin, mitomycin/vinblastine/cisplatin or vinorelbine/cisplatin. RESULTS: Chemotherapy was given before surgery in 3% of patients whilst 97% received adjuvant chemotherapy. Baseline characteristics were: median age 61 years, 69% male, 48% squamous cell, 93% WHO PS 0-1, 27% stage I, 38% stage II, and 34% stage III. Complete resection was achieved in approximately 95% of patients. In the C group, 13% received no chemotherapy, 21% one or two cycles, and 64% all three cycles of their prescribed chemotherapy (60% of the latter with no delays or modification). 30% had grade 3/4 toxicity, mainly haematological, nausea/vomiting and neutropenic fever, and six patients were reported as having a treatment-related death. 198 (52%) of patients have died, but there is currently no evidence of a benefit in overall survival to the C group: HR 1.02 (95% CI 0.77-1.35), P = 0.90). CONCLUSIONS: This trial has failed to observe a survival benefit with adjuvant chemotherapy following complete resection of stage I-III NSCLC. However, the hazard ratio and 95% confidence intervals are consistent with the previously reported meta-analysis and two large recently reported trials, which suggest a small survival benefit with cisplatin-based chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosell, R., Gomez-Codina, J., Camps, C., Maestre, J., Padille, J., Canto, A., Mate, J. L., Li, S., Roig, J., Olazabal, A., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401203300301 · Cited by 1,261
Roth, J. A., Fossella, F., Komaki, R., Ryan, M. B., Putnam, J. B., Lee, J. S., Dhingra, H., De Caro, L., Chasen, M., McGavran, M., et al. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.9.673 · Cited by 1,111
Keller, S. M., Adak, S., Wagner, H., Herskovic, A., Komaki, R., Brooks, B. J., Perry, M. C., Livingston, R. B., & Johnson, D. H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010263431703 · Cited by 446
Cited by
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citationVinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Douillard, J.-Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, A., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573
Treatment of Stage I and II Non-small Cell Lung Cancer
Howington, J. A., Blum, M. G., Chang, A. C., Balekian, A. A., & Murthy, S. C. (2013) · Chest · doi:10.1378/chest.12-2359 · Cited by 1,440
Goldstraw, P., Ball, D., Jett, J. R., Le Chevalier, T., Lim, E., Nicholson, A. G., & Shepherd, F. A. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62101-0 · Cited by 711
Crinò, L., Weder, W., van Meerbeeck, J., & Felip, E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq207 · Cited by 539
Treatment of Stage III Non-small Cell Lung Cancer
Ramnath, N., Dilling, T. J., Harris, L. J., Kim, A. W., Michaud, G. C., Balekian, A. A., Diekemper, R., Detterbeck, F. C., & Arenberg, D. A. (2013) · Chest · doi:10.1378/chest.12-2360 · Cited by 442
Felip, E., Rosell, R., Maestre, J. A., Rodríguez-Paniagua, J. M., Morán, T., Astudillo, J., Alonso, G., Borro, J. M., González-Larriba, J. L., Torres, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6204 · Cited by 430
Arriagada, R., Dunant, A., Pignon, J.-P., Bergman, B., Chabowski, M., Grunenwald, D., Kozlowski, M., Le Péchoux, C., Pirker, R., Pinel, M.-I. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2272 · Cited by 394
One Hundred Years of Lung Cancer
Spiro, S. G., & Silvestri, G. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-531oe · Cited by 379
Self-citationPisters, K. M. W., Evans, W. K., Azzoli, C. G., Kris, M. G., Smith, C. A., Desch, C. E., Somerfield, M. R., Brouwers, M. C., Darling, G., Ellis, P. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1226 · Cited by 363
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
Burdett, S., Pignon, J. P., Tierney, J., Tribodet, H., Stewart, L., Le Pechoux, C., Aupérin, A., Le Chevalier, T., Stephens, R. J., Arriagada, R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011430 · Cited by 360
Self-citationKratz, J. R., He, J., Van Den Eeden, S. K., Zhu, Z.-H., Gao, W., Pham, P. T., Mulvihill, M. S., Ziaei, F., Zhang, H., Su, B., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61941-7 · Cited by 333
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
Daly, M. E., Singh, N., Ismaila, N., Antonoff, M. B., Arenberg, D. A., Bradley, J., David, E., Detterbeck, F., Früh, M., Gubens, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02528 · Cited by 283
A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer
Sandoval, J., Mendez-Gonzalez, J., Nadal, E., Chen, G., Carmona, F. J., Sayols, S., Moran, S., Heyn, H., Vizoso, M., Gomez, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5516 · Cited by 278
Douillard, J.-Y., Tribodet, H., Aubert, D., Shepherd, F. A., Rosell, R., Ding, K., Veillard, A.-S., Seymour, L., Le Chevalier, T., Spiro, S., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c814e7 · Cited by 252
Self-citationVaidya, P., Bera, K., Gupta, A., Wang, X., Corredor, G., Fu, P., Beig, N., Prasanna, P., Patil, P. D., Velu, P. D., et al. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30002-9 · Cited by 134
“Interestingly, some other clinical trials, including the Big Lung Trial (BLT; N=381)(7) and Adjuvant Lung Cancer Project Italy (ALPI; N=1088)(8) have shown no statistically significant benefit for either 5-year OS or disease-free survival (DFS).”
Metadata
- Authors
- WALLER, D., PEAKE, M., STEPHENS, R., GOWER, N., MILROY, R., PARMAR, M., RUDD, R., SPIRO, S., & ONBEHALFOFALLBLTPARTICIPANTS
- Venue
- European Journal of Cardio-Thoracic Surgery
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07
- Volume
- 26
- Issue
- 1
- Pages
- 173-182
- ISSN
- 1010-7940 (ISSN-L)
- OpenAlex
- W2025577038
- Cited by
- 387
- References
- 4
- FWCI
- 23.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.